On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Immun System I.M.S. AB's own share of each project, not the project's full budget.
- FP7 (2007 to 2013)€2.0M · 1 project
Projects
1 EU-funded project, newest first. Each links to the official record.
- IMPACTTPartner
Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment
FP7 (2007 to 2013) · 2011–2016 · Project on CORDIS ↗
€2.0Mtheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
- Institut National de la Sante et de la Recherche MedicaleFrance · 1 shared project
- Uppsala UniversitetSweden · 1 shared project
- Region HovedstadenDenmark · 1 shared project
- Heinrich-Heine-Universitaet DuesseldorfGermany · 1 shared project
- Region StockholmSweden · 1 shared project
- Mukoviszidose Institut - Gemeinnützige Gesellschaft Fur Forschung und TherapieentwicklungGermany · 1 shared project
- Consorzio Italiano Per la Ricerca In Medicina (C.i.r.m.)Italy · 1 shared project
- Valstybinis Moksliniu Tyrimu Institutas Inovatyvios Medicinos CentrasLithuania · 1 shared project
- Cystic Fibrosis Europe eVGermany · 1 shared project
Fields it works in
Research fields recorded on its Horizon projects.
- antibiotics
- bacteriology
- mortality
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.